Your session is about to expire
← Back to Search
Bulking Agent
Bulking Agent vs Sling for Stress Urinary Incontinence (BASIS Trial)
N/A
Recruiting
Led By Emily Lukacz, MD
Research Sponsored by NICHD Pelvic Floor Disorders Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Normal voiding function as demonstrated by PVR less than 150 mL
Be older than 18 years old
Must not have
Anterior/apical vaginal prolapse beyond the hymen (greater than 0 on POPQ)
Urge-predominant mixed UI by UDI-6 despite stable therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from 3 to 12 months post-intervention.
Awards & highlights
No Placebo-Only Group
Summary
"This trial involves 358 women with stress urinary incontinence who did not find relief with conservative treatments. The goal is to compare the effectiveness of two different treatments, transurethral bulking agent
Who is the study for?
This trial is for women who have stress urinary incontinence (SUI) or mixed urinary incontinence with a stress component, and haven't found relief from conservative treatments. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and agree to follow the study procedures.
What is being tested?
The trial is testing two different treatments for SUI: Bulkamid Transurethral Bulking Agent injections versus the Solyx Single-incision Sling procedure. It's designed to see which one is more effective at improving symptoms after 12 months.
What are the potential side effects?
Potential side effects are not detailed here, but generally, bulking agents can cause temporary discomfort or urinary issues, while slings may lead to pain at the incision site, problems urinating, or infection.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I can empty my bladder properly.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My vaginal prolapse extends beyond the hymen.
Select...
I have strong, sudden urges to urinate despite treatment.
Select...
I am scheduled for surgery on my uterus, urethra, or pelvic area.
Select...
I have had cancer or radiation treatment in my pelvic area.
Select...
I have had surgery to control urinary leakage.
Select...
I have a condition where my bladder doesn't function properly due to nerve damage.
Select...
I am currently using a pessary for stress urinary incontinence.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from 3 months to 36 months post-intervention.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from 3 months to 36 months post-intervention.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Subjective success measured by Patient Global Impression-Improvement [PGI-I] (>2) for TBA vs. SIS at 12 months.
Secondary study objectives
Blood Loss
Change in Incontinence Questionnaire-Urinary Incontinence Short Form [ICIQ-SF] score
Condition improvement measured by Patient Global Impression of Severity [PGI-S] for TBA vs. SIS
+18 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Active Control
Group I: Solyx Single-incision SlingActive Control1 Intervention
Solyx Single-incision Sling
Group II: Bulkamid Transurethral Bulking AgentActive Control1 Intervention
Bulkamid Transurethral Bulking Agent
Find a Location
Who is running the clinical trial?
Kaiser PermanenteOTHER
556 Previous Clinical Trials
27,732,378 Total Patients Enrolled
10 Trials studying Urinary Incontinence
4,083 Patients Enrolled for Urinary Incontinence
RTI InternationalOTHER
197 Previous Clinical Trials
939,790 Total Patients Enrolled
4 Trials studying Urinary Incontinence
1,232 Patients Enrolled for Urinary Incontinence
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
2,067 Previous Clinical Trials
2,747,106 Total Patients Enrolled
13 Trials studying Urinary Incontinence
3,004 Patients Enrolled for Urinary Incontinence
Duke UniversityOTHER
2,462 Previous Clinical Trials
2,968,562 Total Patients Enrolled
6 Trials studying Urinary Incontinence
1,547 Patients Enrolled for Urinary Incontinence
University of Texas Southwestern Medical CenterOTHER
1,088 Previous Clinical Trials
1,059,352 Total Patients Enrolled
4 Trials studying Urinary Incontinence
1,059 Patients Enrolled for Urinary Incontinence
University of ChicagoOTHER
1,062 Previous Clinical Trials
839,778 Total Patients Enrolled
2 Trials studying Urinary Incontinence
386 Patients Enrolled for Urinary Incontinence
University of California, San DiegoOTHER
1,189 Previous Clinical Trials
1,587,515 Total Patients Enrolled
12 Trials studying Urinary Incontinence
6,146 Patients Enrolled for Urinary Incontinence
NICHD Pelvic Floor Disorders NetworkLead Sponsor
15 Previous Clinical Trials
4,508 Total Patients Enrolled
7 Trials studying Urinary Incontinence
2,141 Patients Enrolled for Urinary Incontinence
University of PennsylvaniaOTHER
2,084 Previous Clinical Trials
42,726,690 Total Patients Enrolled
9 Trials studying Urinary Incontinence
1,989 Patients Enrolled for Urinary Incontinence
Women and Infants Hospital of Rhode IslandOTHER
114 Previous Clinical Trials
39,992 Total Patients Enrolled
8 Trials studying Urinary Incontinence
2,245 Patients Enrolled for Urinary Incontinence